Obagi Medical Announces the Launch of Retinol + PHA Refining Night Cream
MWN-AI** Summary
Obagi Medical has unveiled its latest innovation, the Retinol + PHA Refining Night Cream, a scientifically formulated skincare product aimed at enhancing overnight skin renewal. Launched on April 22, 2025, this cream combines Entrapped Retinol, known for effective skin renewal, with Polyhydroxy Acid (PHA), a gentle exfoliant that promotes cell turnover while preserving the skin barrier's integrity. This unique formulation is particularly beneficial for individuals with sensitive skin or those who have not previously used retinol.
The distinguishing feature of this night cream is its dual-action, slow-release technology. The Entrapped Retinol disperses gradually into the skin, maximizing efficacy and minimizing irritation typically associated with retinoids. In contrast, PHA’s larger molecular size makes it less irritating than traditional exfoliants like AHAs and BHAs, allowing for effective resurfacing and skin hydration.
Dr. Suzan Obagi, the Chief Medical Director at Obagi, emphasizes that patient compliance is crucial for achieving desired results, stating that this product enhances tolerate nightly use. Clinical studies showcase its effectiveness, reporting notable improvements, including a 29% increase in skin smoothness and a 90% reduction in the appearance of blemishes.
The cream is additionally enriched with eight hydrating and soothing ingredients, including Sodium Hyaluronate and Vitamin E, further promoting skin resilience and moisture retention. Priced at $135, the Retinol + PHA Refining Night Cream will be accessible through professional channels and available for purchase on Obagi's website starting May 5, 2025. As the fastest-growing professional skincare brand in the U.S. in 2024, Obagi continues to lead with innovative solutions tailored to meet diverse skincare needs.
MWN-AI** Analysis
Obagi Medical’s launch of the Retinol + PHA Refining Night Cream represents a significant advancement in the skincare market, underscoring the brand's commitment to delivering cutting-edge, effective products. With its dual-action formulation leveraging Entrapped Retinol and Polyhydroxy Acid (PHA), this product addresses the growing consumer demand for gentler skincare solutions without compromising on efficacy. As sensitive skin becomes an increasingly prevalent concern among consumers, the launch positions Obagi favorably within a competitive landscape.
Given Obagi's recent recognition as the fastest-growing professional skincare brand in the U.S., the market outlook appears promising. This new product not only broadens their portfolio but also enhances their appeal to a broader consumer base, including those previously hesitant to use retinol due to irritation fears. The clinical results from the four-week study, showcasing significant improvements in skin texture and tone, further validate the product's effectiveness and provide a strong selling point in marketing efforts.
From an investment perspective, Obagi, as a subsidiary of Waldencast plc (NASDAQ: WALD), offers a compelling opportunity. The strategic positioning of Obagi within Waldencast’s broader multi-brand platform can harness operational efficiencies and market responsiveness, cultivating increased sales and brand loyalty. Moreover, the trend toward clean, science-backed beauty products aligns with consumer preferences, further enhancing market potential.
As this product hits the consumer market on May 5, 2025, potential investors should closely monitor sales performance and consumer reception. Continued investment in R&D, as evidenced by this launch, coupled with strategic marketing initiatives, could amplify Obagi's growth trajectory. Observers should consider forecasting future market share gains, driven by innovative products like the Retinol + PHA Refining Night Cream. Thus, maintaining a bullish stance on Waldencast stocks could be prudent, especially as consumer confidence in professional skincare continues to rise.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
A Scientific Breakthrough in Skin Renewal: A Clinically Proven Dual-Action, Slow-Release, Overnight Skin Renewal Cream for a Resurfaced, Smoother, and More Even-Looking Complexion
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Obagi Medical ("Obagi"), the fastest-growing professional skincare brand in the U.S. in 2024* and a subsidiary of Waldencast plc, (NASDAQ: WALD) (“Waldencast”), proudly introduces its latest breakthrough: Retinol + PHA Refining Night Cream. This advanced formulation is engineered to optimize skin renewal by leveraging the efficacy of Entrapped Retinol with the scientifically proven gentle exfoliating properties of Polyhydroxy Acid (PHA) Gluconolactone. This synergistic combination enhances cell turnover while reinforcing the skin barrier, resulting in a visibly refined, smoother, and more even complexion.
Expanding on Obagi’s trusted retinol portfolio, this innovative formula incorporates PHA—a next-generation exfoliant with a larger molecular structure than Alpha Hydroxy Acids (AHAs) and Beta Hydroxy Acids (BHAs). This distinction allows for effective resurfacing with minimal irritation, making it ideal for individuals seeking to improve skin texture and tone while maintaining hydration and skin barrier integrity. Additionally, the formula features Entrapped Retinol, a slow-release delivery technology that gradually delivers retinol into multiple layers of the skin over time. This controlled release helps maximize efficacy while minimizing the irritation commonly associated with vitamin A products. The result is an effective yet gentle introduction to retinol, suitable for beginners and those with sensitive skin who may struggle with stronger retinoids.
“Patient compliance is the key to achieving visible results. By using a slow-release, encapsulated retinol combined with a gentle exfoliating and hydrating PHA, this formula makes it easier for patients to tolerate nightly use,” said Dr. Suzan Obagi, Chief Medical Director at Obagi. “As a result, they may experience improved skin texture and a noticeable reduction in blemishes.”
Retinol + PHA Refining Night Cream is fortified with eight additional dermatologically recognized ingredients to support hydration, minimize irritation, and enhance skin resilience. These ingredients include:
- Sodium Hyaluronate – A potent humectant that deeply hydrates and retains moisture.
- Vitamin E (Tocopherol) – A powerful antioxidant that shields against oxidative stress while nourishing the skin.
- Squalane – A bio-compatible lipid that enhances hydration, reinforces the skin barrier, and improves texture.
- Glycerin – A clinically proven hydrating agent that maintains moisture balance and supports skin resilience.
A four-week clinical study demonstrated the efficacy of Retinol + PHA Refining Night Cream, with participants experiencing significant improvements in skin texture and tone, including:
- 29% increase in skin smoothness*
- 10% improvement in skin tone evenness*
- 90% of users reporting visibly smoother skin texture*
- 90% observing a reduction in the appearance of blemishes*
“At Obagi, our mission is to transform skin. We wanted to create a retinol solution that delivers real results while being accessible to those with sensitive skin, blemish concerns, or who aren’t ready for higher-strength retinoids," said Justin Giouzepis, Chief Marketing Officer of Obagi. "This formula was designed with both professionals and their patients in mind—addressing unmet needs with a gentle yet effective approach. We’re thrilled to report that our clinical data found that in just eight weeks, there was a 2.3x increase in the number of participants who felt comfortable in their own skin.”
The Retinol + PHA Refining Night Cream, priced at $135 is now available through partnering professional channels. They will be available for customers to purchase on Obagi.com on 5.5.2025.
*Results based on a 2024-2025 8-week clinical test. Data on file at Obagi Cosmeceuticals LLC.
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm ® System, Obagi products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,* Obagi empowers individuals to achieve healthy, beautiful skin. The brand continues to lead in physician-recommended skincare solutions and is recognized as the #1 Physician-Recommended Brand for At-Home Skincare Products for Hyperpigmentation, Fine Lines & Wrinkles, and Sagging Skin & Loss of Elasticity.** More information about Obagi is available on the brand’s website, https://www.obagi.com .
*Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
**According to Kline’s Physician- Dispensed Skin Care: U.S. Perception and Satisfaction Survey 2023.
About Waldencast
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the business combination with Obagi Cosmeceuticals and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset-light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com/ .
Media Contact:
obagi@purplepr.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/19348f80-4f45-44c4-990a-dc3de7df67b7
FAQ**
How does the innovative Entrapped Retinol technology in Obagi's new Retinol + PHA Refining Night Cream compare to other retinol products on the market, and what potential does it have for driving sales growth for Waldencast Acquisition Corp. WALD?
Given the impressive clinical study results, how might the market respond to the launch of Retinol + PHA Refining Night Cream, and what impact could this have on Obagi's position as a subsidiary of Waldencast Acquisition Corp. WALD?
In what ways does the partnership with professional channels enhance the market reach for Retinol + PHA Refining Night Cream, and how could this strategy benefit Waldencast Acquisition Corp. WALD in terms of revenue growth?
With Obagi's reputation as the fastest-growing professional skincare brand, how does the introduction of this product align with the overall strategic vision of Waldencast Acquisition Corp. WALD for future product innovations?
**MWN-AI FAQ is based on asking OpenAI questions about Waldencast plc (NASDAQ: WALD).
NASDAQ: WALD
WALD Trading
-7.34% G/L:
$1.665 Last:
306,947 Volume:
$1.72 Open:
